Dr. Lisa K. Jennings
Lisa K. Jennings
Chief Scientific Officer, Ph.D.
Dr. Jennings is a tenured Professor of Medicine at the University of Tennessee Health Science Center (UTCHS) in Memphis, Tennessee, USA. She has secondary appointments at the rank of Professor in the Departments of Molecular Sciences and Surgery as well as in the Joint Program of Biomedical Engineering at UTHSC and the University of Memphis. Dr. Jennings attended graduate school at UTHSC and completed her Ph.D. thesis research at St. Jude Children's Research Hospital and the Gladstone Foundation Laboratories in San Francisco. She completed a post-doctoral fellowship at St. Jude Children's Research Hospital where she was a Leon Journey Fellow, and was appointed to the faculty of UTCHS in 1985.
Dr. Jennings served as Director of the UTCHS Vascular Biology Center of Excellence (www.utmem.edu/vascular) and of the TN-AR-MS (TAM) Clinical Research Consortium from 1998-2014. Dr. Jennings has an established research program in the area of thrombosis and hemostasis, specifically the function of platelet surface membrane receptors and associated signaling pathways, and vascular injury response. She has primarily focused on the biology of the platelet receptors as well as the tetraspanin superfamily that augments neointimal hyperplasia. She is an expert on antiplatelet and antithrombin targets and pharmacotherapy including the design and conduct of the pharmacodynamic assessment of these agents in pre-clinical studies and in clinical trials. Clinical trials include IMPACT, IMPACT II, PRIDE, ESPRIT, and PROTECT trials of eptifibatide (Integrilin), PYRAMID (YM337), ORATOR, TIMI15A and B (Klerval), PICOLO (clopidogrel), multiple TAM clinical trials, TRACER, ATLAS, INNOVATE, and APEX.
In addition, her research interests focus on the development of medical implants that inhibit neointimal hyperplasia and advance healing by programmed drug elution. Other research efforts in the Vascular Biology Center concentrate on vascular injury response, particularly signaling pathways associated with smooth muscle migration and proliferation including restenosis. Dr. Jennings has more than 110 publications in peer-reviewed journals and 100 abstracts. She has received grant support by the NIH, the American Heart Association or industry since 1983.
Dr. Jennings has expertise in creating, communicating, executing and sustaining strategic initiatives. Her extensive work within the translational science field has afforded her many partnering opportunities in academia and industry. She has acted as a resource and translated strategies into actionable plans as a member of advisory boards for pharmaceutical and biotech companies. In 2008, she founded a specialty translational laboratory company that provides consultative, R&D and clinical trial support services to pharmaceutical and device industries.